IP Library › Granted Patent US 12,509,598
Granted Patent B2
US 12,509,598 · App. 17/691,524 · Granted Dec 30, 2025

Process solution composition for polymer treatment comprising a fluorine compound, a ketone solvent, and a polar aprotic solvent

Inventors: Soon-Hong Pang (Jeollabuk-do, KR); Han-Byeol Kang (Gyeonggi-do, KR); Sung-Sik Kim (Jeollabuk-do, KR); Tae-Hee Kim (Jeollabuk-do, KR)
Assignee: DONGWOO FINE-CHEM CO., LTD.
C09D9/005C11D3/245C11D3/28C11D3/30G03F7/425C11D2111/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,509,598
App. No.
17/691,524
Granted
Dec 30, 2025
Kind
B2
Abstract

The present disclosure relates to a process solution composition for polymer treatment comprising: a fluorine compound; a ketone-based solvent; and a polar aprotic solvent, wherein the ketone-based solvent is one or more selected from the group consisting of compounds represented by Chemical Formula 1 or Chemical Formula 2, and has an effect capable of preventing damage to various types of metals while improving the power of removing an adhesive polymer remaining on the wafer circuit surface in a semiconductor manufacturing process.

Claims (25)

1 . A process solution composition for polymer treatment comprising:

A) 0.1 to 30% by weight of a fluorine compound;

B) from 5 to 90% by weight of one or more ketone-based solvent represented by the following Chemical Formula 1 or Chemical Formula 2;

wherein R 1 and R 2 are each independently a C 1 -C 18 linear or branched hydrocarbon group or a C 3 -C 18 cycloaliphatic hydrocarbon group;

R 3 and R 5 are each independently a C 1 -C 18 linear or branched aliphatic hydrocarbon group or a C 3 -C 18 cycloaliphatic hydrocarbon group; and

R 4 is a C 1 -C 18 linear or branched divalent aliphatic hydrocarbon group;

C) less than 4% by weight water; and

D) one or more polar aprotic solvent(s) selected from the group consisting of:

i) an amide-based solvent selected from the group consisting of N,N-dimethylformamide, N,N-diethylformamide, N,N-dipropylformamide, N,N-dimethylacetamide, N,N-diethylacetamide, N,N-dipropylacetamide, N-ethyl-N-methylacetamide, N,N-dimethylpropionamide, N,N-dimethylbutyramide, N,N-dimethylisobutyramide, N,N-dimethylpentanamide, N,N-dimethylpropanamide, N,N-diethylpropanamide, and N,N-dibutylpropanamide;

ii) a morpholine-based solvent selected from the group consisting of N-methylmorpholine, N-ethylmorpholine, N-arylmorpholine, N-butylmorpholine, and N-isobutylmorpholine;

iii) a pyrrolidine-based solvent selected from the group consisting of 1-ethylpyrrolidine, 1-propylpyrrolidine, 1-butylpyrrolidine, tert-butyl pyrrolidine, 1-(1-phenylpentan-2-yl) pyrrolidine, and 1-(1-cyclohexen-1-yl) pyrrolidine;

iv) a pyrrolidone-based solvent selected from the group consisting of N-methylpyrrolidone, N-ethylpyrrolidone, and N-vinylpyrrolidone;

v) a urea-based solvent selected from the group consisting of tetramethylurea, tetraethylurea, and tetrabutylurea;

vi) a phosphate-based solvent selected from the group consisting of triethyl phosphate, tributyl phosphate, triamyl phosphate, and triaryl phosphate;

vii) an oxazolidone-based solvent selected from the group consisting of 2-oxazolidone and 3-methyl-2-oxazolidone; and

viii) a piperazine-based solvent selected from the group consisting of dimethylpiperazine and dibutylpiperazine, wherein other than water, the process solution composition does not comprise a compound comprising a hydroxide group.

2 . The process solution composition of claim 1 , wherein the ketone-based solvent includes a compound having the sum of carbon atoms of 3 or more and 30 or less.

3 . The process solution composition of claim 1 , wherein the ketone-based solvent and the polar aprotic solvent have a mixing ratio of 1:9 to 9:1.

4 . The process solution composition of claim 1 , wherein the mixed solvent of the ketone-based solvent and the polar aprotic solvent has a Hansen solubility parameter value range satisfying the following:

δ D : 15.5 to 19.0 [MPa 1/2 ]

δ P : 7.5 to 15.5 [MPa 1/2 ]

δ H : 4.5 to 9.5 [MPa 1/2 ].

5 . The process solution composition of claim 1 , wherein the ketone-based solvent is one or more selected from the group consisting of 2-butanone, dicyclopropyl ketone, cyclopropyl methyl ketone, 3-pentanone, 2-pentanone, 3-methyl-2-pentanone, acetylacetone, 4-methyl-2-pentanone, 2-methyl-3-pentanone, 3-hexanone, 2-hexanone, 1-cyclopentylethanone, 3-methyl-2-hexanone, 2-methyl-3-hexanone, isoamyl ketone, amyl ketone, 4-heptanone, 3-heptanone, 2-heptanone, 5-nonanone, 2,4-dimethyl-3-pentanone, ethyl isobutyl ketone, 3-octanone, 5-methyl-2-hexanone, 5-methyl-3-heptanone, 3-methyl-4-heptanone, 2,5-dimethyl-3-hexanone, 2,6-dimethyl-4-hexanone, 2-undecanone, and 2,6-dimethyl-4-heptanone.

6 . The process solution composition of claim 1 , wherein the fluorine compound is one or more selected from the group consisting of alkylammonium fluoride, alkylphosphonium fluoride, and alkylsulfonium fluoride.

7 . The process solution composition of claim 1 , wherein the process solution composition for polymer treatment removes a reticulated polymer and a linear polymer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: PANG, SOON-HONG; KANG, HAN-BYEOL; KIM, SUNG-SIK; KIM, TAE-HEE
To: DONGWOO FINE-CHEM CO., LTD.
Reel/Frame 059359/0879 →
Priority Claims (1)
KR 10-2021-0033882 · Mar 16, 2021 · national
Continuity (1)
Related Publication 20220298366A1 · Sep 22, 2022
References Cited (68)
US 6652665B1 · Sachdev et al. · 2003 [cited by applicant]
US 6773873B2 · Seijo et al. · 2004 [cited by applicant]
US 6818608B2 · Moore · 2004 [cited by applicant]
US 7192910B2 · Wojtczak et al. · 2007 [cited by applicant]
US 8802608B2 · Shimada et al. · 2014 [cited by applicant]
US 10460954B2 · Cooper et al. · 2019 [cited by applicant]
US 11175585B2 · Murayama et al. · 2021 [cited by applicant]
US 11739048B2 · Pang et al. · 2023 [cited by applicant]
US 20050003977A1 · Itano et al. · 2005 [cited by applicant]
US 20050014667A1 · Aoyama et al. · 2005 [cited by applicant]
US 20050187118A1 · Haraguchi · 2005 [cited by examiner]
US 20060003910A1 · Hsu et al. · 2006 [cited by applicant]
US 20060234516A1 · Hong et al. · 2006 [cited by applicant]
US 20060237392A1 · Auger et al. · 2006 [cited by applicant]
US 20070179072A1 · Rao et al. · 2007 [cited by applicant]
US 20080004197A1 · Kneer · 2008 [cited by applicant]
US 20090032766A1 · Rajaratnam · 2009 [cited by examiner]
US 20090093107A1 · Lee et al. · 2009 [cited by applicant]
US 20100163788A1 · Visintin et al. · 2010 [cited by applicant]
US 20100197136A1 · Shimada et al. · 2010 [cited by applicant]
US 20120181668A1 · Doll · 2012 [cited by examiner]
US 20170200619A1 · Cooper et al. · 2017 [cited by applicant]
US 20180230401A1 · Sakanishi et al. · 2018 [cited by applicant]
US 20180265819A1 · Kang et al. · 2018 [cited by applicant]
US 20190064672A1 · Murayama et al. · 2019 [cited by applicant]
US 20200013618A1 · Weng · 2020 [cited by examiner]
US 20200339523A1 · Hoogboom · 2020 [cited by examiner]
US 20220186152A1 · Tanabe · 2022 [cited by examiner]
US 20220195352A1 · Sugo et al. · 2022 [cited by applicant]
CA 2544209A1 · 2005 [cited by applicant]
CN 1575331A · 2005 [cited by applicant]
CN 1643454A · 2005 [cited by applicant]
CN 101013273A · 2007 [cited by applicant]
CN 103804980A · 2014 [cited by applicant]
CN 108435101A · 2018 [cited by applicant]
CN 109075035A · 2018 [cited by applicant]
EP 1975987A2 · 2008 [cited by applicant]
JP 2006009006A · 2006 [cited by applicant]
JP 2006295118A · 2006 [cited by applicant]
JP 2007027382A · 2007 [cited by applicant]
JP 2009194087A · 2009 [cited by applicant]
JP 2009212383A · 2009 [cited by applicant]
JP 2010515246A · 2010 [cited by applicant]
JP 2017519862A · 2017 [cited by applicant]
JP 2020189927A · 2020 [cited by applicant]
KR 20030093974A · 2003 [cited by applicant]
KR 1020090096728A · 2009 [cited by applicant]
KR 1020100044777A · 2010 [cited by applicant]
KR 102014005994A · 2014 [cited by applicant]
KR 1020140060389A · 2014 [cited by applicant]
KR 20150016430A · 2015 [cited by applicant]
KR 1020160039945A · 2016 [cited by applicant]
KR 1020160073288A · 2016 [cited by applicant]
KR 20160070385A · 2016 [cited by applicant]
KR 20160070386A · 2016 [cited by applicant]
KR 1020160087089A · 2016 [cited by applicant]
KR 1020160101511A · 2016 [cited by applicant]
KR 1020170015452A · 2017 [cited by applicant]
KR 102192954B1 · 2020 [cited by applicant]
TW 200641562A · 2006 [cited by applicant]
TW 202106865A · 2021 [cited by applicant]
WO 2007120259A2 · 2007 [cited by applicant]
WO 2008080097A2 · 2008 [cited by applicant]
WO 2008157345A2 · 2008 [cited by applicant]
WO 2010039936A2 · 2010 [cited by applicant]
WO 2009013987A · 2010 [cited by applicant]
WO 2020235605A1 · 2020 [cited by applicant]
Shao, “Haiyang Fushi Yu Shengwu Wusun Fanghu Yanjiu”, Jilin University Press, Mar. 2019. [cited by applicant]